(USD) | Feb 2024 | Q/Q |
---|---|---|
Revenue | 75.2MM | -5% |
Gross Profit | 35.9MM | -11% |
Cost Of Revenue | 39.3MM | +1% |
Operating Income | -199.9MM | - |
Operating Expenses | 242.4MM | - |
Net Income | -187.7MM | - |
R&D | 8.2MM | -5% |
G&A | 10.6MM | +14% |
Marketing | 25.4MM | -0% |
Amortization | 3.3MM | -8% |
Interest Expense | -394K | -26% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Even if it's not a huge purchase, we think it was good to see that James Clemmer, the CEO, President & Director of...
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript April 4, 2024 AngioDynamics, Inc. misses on earnings expectations. Reported EPS is $-0.16 EPS, expectations were $-0.14. AngioDynamics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to […]
AngioDynamics ( NASDAQ:ANGO ) Third Quarter 2024 Results Key Financial Results Revenue: US$75.2m (down 6.9% from 3Q...
Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.
AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
Q3 2024 AngioDynamics Inc Earnings Call
Thursday, the FDA granted 510(k) clearance to AngioDynamics Inc’s (NASDAQ:ANGO) AlphaVac F1885 System for pulmonary embolism (PE). The expanded FDA indication allows for the utilization of the AlphaVac F1885 System for PE, which broadens the applicability of the AlphaVac F1885 System in the non-surgical removal of thrombi or emboli from the venous vasculature. The indication expands treatment options for patients with PE, reducing thrombus burden and improving right ventricular function. Also Re
ANGO's Earnings Miss Analyst Projections Despite Revenue Growth
LATHAM, N.Y., April 04, 2024--AngioDynamics, Inc. (NASDAQ: ANGO):
LATHAM, N.Y., April 04, 2024--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States Food and Drug Administration (FDA) has cleared the AlphaVac F1885 System for the treatment of pulmonary embolism (PE), enhancing its utility in critical medical scenarios such as PE.